Add to that recruitment will imminently commence in the phase 1...

Add to that recruitment will imminently commence in the phase 1 FDA study for RAD301 - read out est Sept 2023.

Based on existing efficacy data under German Medical Drug Act (66 patients) and at Fortis medical (17 patients) there's a high probability of success and
Importantly, this goes straight to phase 2/3 (pivotal) trial also.

In short, within 18 months we could be at the point TLX went over 1bn with not 1 but 2 pivotal trials, with plenty of catalysts along the way..

As a side note, based on this: "it was "their suggestion" (referring to the FDA) to submit the IND for a Phase 2b/3 (pivotal trial)" we should reasonably at least be at the mc CU6 is not 75-80% less.